title: A comparative test of fifteen compounds against all known human rhinovirus serotypes as a basis for a more rational screening program.
abstract: A systematic evaluation of 15 rhinovirus capsid-binding agents against all 100 serotyped human rhinoviruses revealed the existence of two virus groups, based upon differential susceptibility to antiviral compounds. Elongated and short-chained compounds preferentially inhibited groups A and B. The positions of the rhinoviruses within a map derived from a multivariate analysis allow for the selection of a panel of 17 rhinoviruses, for which the median antiviral inhibitory value against them will accurately predict the median value against 100 serotypes. This rationalizes the search for broad-spectrum capsid-binding antirhinovirus drugs, or combinations of drugs with complementary spectra that may be necessary to effectively inhibit both type A and type B viruses.
authors.affiliation: Janssen Research Foundation, Beerse, Belgium.
authors.forename: K
authors.initials: K
authors.lastname: Andries
authors.forename: B
authors.initials: B
authors.lastname: Dewindt
authors.forename: J
authors.initials: J
authors.lastname: Snoeks
authors.forename: R
authors.initials: R
authors.lastname: Willebrords
authors.forename: R
authors.initials: R
authors.lastname: Stokbroekx
authors.forename: P J
authors.initials: PJ
authors.lastname: Lewi
mesh_terms: D000998:Antiviral Agents / Q000378:metabolism / Q000494:pharmacology*; D002213:Capsid / Q000378:metabolism; D015195:Drug Design; D004353:Drug Evaluation, Preclinical; D007555:Isoxazoles / Q000378:metabolism / Q000494:pharmacology; D008954:Models, Biological; D012229:Rhinovirus / Q000145:classification / Q000187:drug effects*; D013329:Structure-Activity Relationship
chemical_list: D000998:Antiviral Agents; D007555:Isoxazoles; C045978:disoxaril